Goldman Sachs Group Inc Biomarin Pharmaceutical Inc Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,592,963 shares of BMRN stock, worth $88 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,592,963

Previous 1,592,963 -0.0%

Holding current value

$88 Million

Previous $113 Million -0.0%

% of portfolio

0.02%

Previous 0.02%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$61.25 - $72.83 $66.4 Million - $78.9 Million	1,083,512 Added 212.68%	1,592,963 $113 Million
Q4 2024 Feb 11, 2025	BUY	$61.93 - $70.49 $3.68 Million - $4.19 Million	59,485 Added 13.22%	509,451 $33.5 Million
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $7.58 Million - $10.3 Million	-109,836 Reduced 19.62%	449,966 $31.6 Million
Q2 2024 Aug 13, 2024	SELL	$74.43 - $92.22 $9.93 Million - $12.3 Million	-133,422 Reduced 19.25%	559,802 $46.1 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $18 Million - $21.2 Million	-214,557 Reduced 23.64%	693,224 $60.5 Million
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $5.47 Million - $7.07 Million	-71,814 Reduced 7.33%	907,781 $87.5 Million
Q3 2023 May 14, 2024	BUY	$85.07 - $94.48 $6.11 Million - $6.78 Million	71,814 Added 7.91%	979,595 $86.7 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $38.7 Million - $43 Million	-455,302 Reduced 31.73%	979,595 $86.7 Million
Q2 2023 May 14, 2024	BUY	$86.68 - $100.3 $26.5 Million - $30.7 Million	306,018 Added 27.11%	1,434,897 $124 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $26.5 Million - $30.7 Million	306,018 Added 27.11%	1,434,897 $124 Million
Q1 2023 May 14, 2024	SELL	$87.74 - $117.27 $3.7 Million - $4.95 Million	-42,172 Reduced 3.6%	1,128,879 $110 Million
Q1 2023 May 11, 2023	SELL	$87.74 - $117.27 $3.7 Million - $4.95 Million	-42,172 Reduced 3.6%	1,128,879 $110 Million
Q4 2022 May 14, 2024	BUY	$80.93 - $108.63 $31.4 Million - $42.2 Million	388,026 Added 49.55%	1,171,051 $121 Million
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $31.4 Million - $42.2 Million	388,026 Added 49.55%	1,171,051 $121 Million
Q3 2022 May 14, 2024	SELL	$82.16 - $96.94 $3.26 Million - $3.85 Million	-39,673 Reduced 4.82%	783,025 $66.4 Million
Q3 2022 Nov 10, 2022	SELL	$82.16 - $96.94 $3.26 Million - $3.85 Million	-39,673 Reduced 4.82%	783,025 $66.4 Million
Q2 2022 May 14, 2024	SELL	$71.48 - $86.85 $6.08 Million - $7.39 Million	-85,083 Reduced 9.37%	822,698 $68.2 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $8.15 Million - $9.91 Million	114,080 Added 16.1%	822,698 $68.2 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $7.91 Million - $9.87 Million	-106,449 Reduced 13.06%	708,618 $54.6 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $48.2 Million - $61.4 Million	-671,512 Reduced 45.17%	815,067 $72 Million
Q3 2021 Nov 10, 2021	BUY	$74.77 - $85.47 $111 Million - $127 Million	1,486,579 New	1,486,579 $115 Million

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Biomarin Pharmaceutical Inc Transaction History